Nepal gives emergency use approval to Bharat Biotech's Covaxin

Nepal's national drug regulatory authority on Saturday granted emergency use approval to Bharat Biotech's Covaxin.

Nepal has reported 275,750 cases and 3,016 deaths so far. It is now only the third country to approve India's indigenously developed Covid vaccine -- also the third COVID-19 vaccine authorised in the country.

According to The Kathmandu Post, a meeting of the drug advisory committee of the Department of Drug Administration decided to issue a conditional emergency use authorisation to India's homegrown government-backed vaccine Covaxin.

COVAXIN, which demonstrated an interim vaccine efficacy of 81 per cent in the Phase 3 clinical trials India, was approved for emergency use in India in January and Zimbabwe cleared it early this month.

Bharat Biotech had applied for emergency use authorisation for its vaccine in Nepal on January 13. Of the three applications filed on January 13, the department had first granted emergency use authorisation to Oxford-AstraZeneca on January 15.

The AstraZeneca vaccine, manufactured by the Serum Institute of India under the name of Covishiled, was then accordingly brought to the country.

Nepal granted emergency use authorisation to BBIBP-CorV vaccine, developed by China's Sinopharm on February 17.

The country has used one million doses of AstraZeneca vaccines provided by India in January under grant assistance in sync with its Neighbourhood First' policy. It is now also awaiting another consignment of 2 million AstraZeneca vaccines from the Serum Institute of India (SII).'